Gilead Reports Positive Phase 3 Results for Livdelzi in Primary Biliary Cholangitis, Demonstrating Significant Improvement in Liver Disease Marker
Gilead Sciences has announced positive topline results from the Phase 3 IDEAL clinical trial evaluating Livdelzi® (seladelpar) in patients with primary biliary cholangitis (PBC), a chronic autoimmune liver disease that can progressively damage the bile ducts and ultimately lead to liver failure if left inadequately controlled. The study demonstrated that treatment with Livdelzi enabled significantly more patients to achieve normalization of alkaline phosphatase (ALP), an important biomarker associated with disease activity and long-term outcomes, compared with placebo after 52 weeks of treatment.
The findings add to the growing body of evidence supporting Livdelzi’s role in the treatment of PBC and further expand understanding of its potential benefits in patients with moderately elevated ALP levels who have historically been underrepresented in clinical trials. According to Gilead, the safety profile observed during the study was consistent with previous clinical experience and revealed no new safety concerns.
The IDEAL trial results build upon the earlier pivotal Phase 3 RESPONSE study, which helped establish Livdelzi as a treatment capable of significantly improving disease-related biomarkers while also addressing pruritus, or severe itching, one of the most burdensome symptoms experienced by people living with PBC.
Addressing an Unmet Need in Primary Biliary Cholangitis
Primary biliary cholangitis is a rare, chronic autoimmune disease in which the body’s immune system mistakenly attacks the small bile ducts within the liver. Over time, ongoing inflammation and bile duct damage can result in scarring, fibrosis, cirrhosis, and eventually liver failure.
The disease primarily affects women and often develops gradually, with symptoms including fatigue, itching, dry eyes, and other complications that can significantly affect quality of life.
For many patients, ursodeoxycholic acid (UDCA) remains the standard first-line treatment. However, a substantial proportion of individuals either fail to achieve adequate disease control with UDCA or are unable to tolerate the therapy. These patients face an increased risk of disease progression and may require additional treatment options to better manage their condition.
The IDEAL study focused specifically on a patient population with inadequately controlled disease despite prior therapy. Participants enrolled in the trial had ALP levels above the upper limit of normal but below 1.67 times the upper limit of normal and had either shown an incomplete response to UDCA or were unable to tolerate the treatment.
Although such patients are frequently encountered in routine clinical practice, they have historically been underrepresented in randomized clinical studies. As a result, there has been limited evidence available to guide treatment decisions for this subgroup.
By specifically studying these individuals, the IDEAL trial sought to address an important gap in the PBC treatment landscape.
Significance of Alkaline Phosphatase Normalization
A central focus of the IDEAL trial was the achievement of ALP normalization, which is increasingly being recognized as an important therapeutic objective in the management of primary biliary cholangitis.
Alkaline phosphatase is a liver enzyme commonly used as a biomarker of disease activity in PBC. Elevated ALP levels often indicate ongoing bile duct injury and inflammation, while persistent elevations have been associated with poorer long-term outcomes.
Research has shown that patients whose ALP levels remain above normal face a higher likelihood of disease progression, liver transplantation, and mortality compared with those who achieve normalization of the biomarker.
Importantly, even modest elevations in ALP can carry clinical significance. Patients with ALP levels between one and 1.67 times the upper limit of normal may still be at increased risk for adverse outcomes despite appearing to have relatively controlled disease.
As understanding of the disease evolves, clinicians are increasingly viewing normalization of ALP—not merely reduction—as a desirable treatment goal.
The IDEAL study was designed to evaluate whether Livdelzi could help patients reach this higher standard of disease control.
Positive Phase 3 IDEAL Trial Results
The trial successfully met its primary endpoint, demonstrating that significantly more patients treated with Livdelzi achieved the predefined composite endpoint compared with those receiving placebo.
The primary endpoint required patients to achieve an ALP level at or below the upper limit of normal while also experiencing at least a 15% reduction from baseline ALP values after 52 weeks of treatment.
This composite measure was selected to ensure that improvements represented both normalization of the biomarker and a meaningful reduction in disease activity.
According to Gilead, treatment with Livdelzi resulted in substantially higher rates of achieving this endpoint compared with placebo, providing evidence that the therapy can effectively improve liver biochemistry in patients with incompletely controlled disease.
The results are particularly notable because the trial enrolled patients with ALP levels that were elevated but not dramatically high. Historically, clinical trials in PBC have often focused on patients with more pronounced biochemical abnormalities.
The IDEAL findings therefore extend the evidence base for Livdelzi into a broader segment of the PBC population and support the concept that ALP normalization may be an achievable target even among patients with moderately elevated enzyme levels.
Building on Earlier Clinical Success
The positive findings from IDEAL complement data previously generated in the Phase 3 RESPONSE trial, which played a pivotal role in establishing Livdelzi’s efficacy profile.
In RESPONSE, Livdelzi demonstrated statistically significant improvements in key disease markers while also reducing pruritus compared with placebo. Those results helped distinguish the therapy within the evolving treatment landscape for primary biliary cholangitis.
Experts believe the new IDEAL data further strengthen confidence in the therapy’s clinical value by demonstrating benefits across a wider range of patients.
Dr. Cynthia Levy, Professor of Clinical Medicine and Hepatology at the University of Miami Miller School of Medicine, emphasized the importance of the findings.
According to Levy, the IDEAL study expands the clinical evidence supporting Livdelzi and reinforces its efficacy and safety profile. She noted that the results provide additional support for considering ALP normalization as a realistic and clinically meaningful treatment goal for patients whose ALP levels fall within the one to 1.67 times upper-limit-of-normal range.
The findings may influence future treatment strategies as clinicians increasingly seek to optimize long-term outcomes through more aggressive control of disease activity.
Consistent Safety Profile
Safety remains a critical consideration in the long-term management of chronic liver diseases, particularly because many patients require ongoing treatment for years.
Gilead reported that the safety profile observed in the IDEAL trial was consistent with previous studies involving Livdelzi and no new safety concerns were identified.
The absence of unexpected adverse events is an encouraging finding for both physicians and patients, as it suggests that the treatment maintains a predictable risk-benefit profile across different patient populations.
Consistency in safety outcomes is especially important when expanding treatment to broader groups of patients, including those with less severe biochemical abnormalities who may be expected to remain on therapy for extended periods.
The IDEAL results therefore provide reassurance that the efficacy benefits observed in the study were achieved without introducing new safety challenges.
Evolving Treatment Goals in PBC
The management of primary biliary cholangitis has evolved significantly in recent years as researchers have gained a better understanding of disease progression and prognostic markers.
Historically, treatment success was often defined by reductions in ALP levels rather than complete normalization. However, accumulating evidence suggests that achieving normal ALP values may be associated with improved long-term outcomes and reduced risk of complications.
This shift in thinking is gradually influencing clinical practice and the design of future studies.
Swati Tole, Senior Vice President of Clinical Development for Inflammation at Gilead Sciences, highlighted the company’s commitment to advancing care in liver diseases.
She noted that addressing persistent unmet needs requires ongoing scientific investigation and emphasized that Gilead remains focused on generating meaningful clinical evidence that can improve understanding of treatment responses and help inform patient care.
According to Tole, as the field increasingly recognizes ALP normalization as an important therapeutic objective, studies such as IDEAL play a critical role in translating scientific insights into tangible benefits for patients.
Implications for Patients and Healthcare Providers
The IDEAL findings may have important implications for both clinicians and individuals living with PBC.
For healthcare providers, the results offer new evidence supporting intervention in patients whose ALP levels remain modestly elevated despite standard treatment. These patients may previously have been considered relatively stable despite continued biochemical abnormalities.
The data suggest that pursuing normalization of ALP may provide additional clinical benefit and potentially reduce the long-term risk of disease progression.
For patients, the findings offer renewed hope that improved disease control may be achievable even when standard therapies do not produce an optimal response.
As treatment goals continue to evolve, therapies capable of helping patients reach normalized liver biomarker levels could play an increasingly important role in comprehensive disease management strategies.
Next Steps for Development and Regulatory Discussions
Gilead has indicated that complete data from the IDEAL study will be presented at an upcoming scientific congress, where investigators and clinicians will have an opportunity to review the findings in greater detail.
The company also plans to engage with regulatory authorities around the world to discuss the implications of the results and explore potential pathways for incorporating the new evidence into regulatory and clinical frameworks.
With positive outcomes now demonstrated across multiple studies, Livdelzi continues to strengthen its position within the treatment landscape for primary biliary cholangitis. The IDEAL trial not only reinforces the therapy’s efficacy and safety profile but also contributes to the growing movement toward ALP normalization as a meaningful treatment objective. As research continues and additional data become available, the findings may help shape future standards of care and improve outcomes for patients living with this chronic and progressive liver disease.
About IDEAL (NCT06060665)
The IDEAL study is a Phase 3, double‑blind, placebo‑controlled trial designed to evaluate Livdelzi in adults living with primary biliary cholangitis (PBC) who have inadequately controlled disease, defined as having alkaline phosphatase (ALP) levels above normal but less than 1.67× ULN despite treatment with ursodeoxycholic acid (UDCA) or with UDCA intolerance.
Its primary objective is to evaluate the effect of Livdelzi treatment at Week 52 compared to placebo, assessing rates of ALP normalization, defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with an ALP value greater than ULN but less than 1.67× ULN. A composite was used for the primary endpoint to ensure rigorous evaluation of ALP normalization over time. The study enrolled 96 adults aged 18–75 years.
About PBC
PBC is a chronic, autoimmune disease of the bile ducts that affects approximately 130,000 Americans. PBC is more common in women and causes liver damage that can progress to liver failure and result in the need for liver transplant, if left untreated. The most common symptoms of PBC are pruritus (chronic itch) and fatigue, which up to 80% of people living with PBC can experience and can profoundly compromise quality of life. Symptoms of PBC are often invisible to others and the journey to a PBC diagnosis can be long and challenging.
There is currently no cure for PBC, and treatment goals include reducing the risk of disease progression and reducing the symptoms related to cholestasis (impaired bile flow), such as cholestatic itch. The effect is primarily measured by an improvement in liver biochemical tests, including the improvement and normalization of alkaline phosphatase (ALP) levels, an important marker associated with long‑term outcomes in PBC.
About Livdelzi
Livdelzi (seladelpar) is an oral PPAR‑delta agonist, or delpar, for the treatment of primary biliary cholangitis (PBC). PPAR‑delta is known to regulate key metabolic and liver disease pathways. Preclinical and clinical data indicate that Livdelzi has anticholestatic, anti‑inflammatory, antipruritic, and antifibrotic effects.
Clinical trial data have shown that Livdelzi can support meaningful improvements in key markers of disease activity, including biochemical response and alkaline phosphatase (ALP) normalization, with durable effects observed over long‑term follow‑up in multiple studies.
Livdelzi has the potential to help address ongoing unmet needs for people living with PBC, including those who remain inadequately controlled on existing therapies. Pruritus is a common symptom of PBC that can significantly impair quality of life, and prior studies have demonstrated improvements in pruritus with Livdelzi compared with placebo.
